P3-029Nab-paclitaxel plus ramucirumab combination therapy as second-line with advanced gastric cancer:Retrospective study

Abstract Background Metastatic advanced gastric cancer(AGC) is predominantly a disease in JAPAN. A Phase II trial show the efficacy and safety of nab-paclitaxel plus ramucirumab combination therapy for previously treated advanced gastric cancer but the benefits of second-line chemotherapy in real world including elderly patients remain uncertain. Methods We retrospectively examined pts with AGC who were treated in Saga-university hospital. The key inclusion criteria were ECOG PS 0-2 and refractory/intolerant to first line treatments. The objective was the efficacy of Ramucirumab plus nab-Paclitaxel as second-line therapy in real-world patients with AGC. Results A total of 14 patients underwent second-line chemotherapy for gastric cancer between 2017 and 2018 at our hospital. We evaluated the outcome in terms of median progressive free survival (PFS) and overall survival (OS) respectively. The ORR assessed was 40.0% and the DCR was 100%. The median PFS was 7.6 months (95% CI 2.1-17.5). The median OS was not reached at the data cutoff. The main treatment-related over grade 2 adverse events were decreased neutrophil count (60%),hypertension (26%) and proteinuria (0%). Conclusions Nab-paclitaxel plus ramucirumab combination therapy shows similar treatment results to the Phase II study and toxicities were safety manageable. This treatment regimen could be a useful second line treatment option for patients with previously treated AGC.